JAZZ Dec 2024 135.000 call
| Previous Close | 2.6200 |
| Open | 2.6200 |
| Bid | 0.1500 |
| Ask | 4.8000 |
| Strike | 135.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 2.6200 - 2.6200 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 22 |
PR NewswireJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). These data will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting in a poster presentation during the Gastrointestinal Cancer – Gastroesophageal, Pancreati
ZacksWhy Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts, including five late-breaking abstracts, featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies being held June 1-5, 2024, in Houston, Texas.
